Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Beam Therapeutics(BEAM.US) Officer Sells US$1.47 Million in Common Stock
$Beam Therapeutics(BEAM.US)$ Officer Evans John M. sold 60,000 shares of common stock on Jun 27, 2024 at an average price of $24.5026 for a total value of $1.47 million.Source: Announcement What is st
Beam Therapeutics Insider Sold Shares Worth $1,470,156, According to a Recent SEC Filing
Form 144 | Beam Therapeutics(BEAM.US) Officer Proposes to Sell 1.47 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 27, $Beam Therapeutics(BEAM.US)$ Officer JOHN M EVANS intends to sell 60,000 shares of its common stock on Jun 27, with a total market value of approximately $1.47 million.
Wells Fargo Maintains Beam Therapeutics(BEAM.US) With Buy Rating
Wells Fargo analyst Yanan Zhu maintains $Beam Therapeutics(BEAM.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 36.9% and a total average return of 12.6% over the
Beam Therapeutics Announced The First Patient Was Treated With BEAM-302, An Investigational In Vivo Base Editing Medicine Designed To Precisely Correct The Underlying Cause Of Severe Alpha-1 Antitrypsin Deficiency, Currently In Phase 1/2 Trial
Express News | Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of Beam-302 in Alpha-1 Antitrypsin Deficiency (Aatd)
CCORF Initiates Beam Therapeutics(BEAM.US) With Hold Rating, Announces Target Price $42
CCORF analyst Mary Kate initiates coverage on $Beam Therapeutics(BEAM.US)$ with a hold rating, and sets the target price at $42.According to TipRanks data, the analyst has a success rate of 0.0% and a
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
Analysts' Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)
Beam Therapeutics: A Hold Rating Amid Controlled R&D Spending and Upcoming Clinical Milestones
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)
Beam Therapeutics Price Target Cut to $33.00/Share From $42.00 by Barclays
Beam Therapeutics Is Maintained at Equal-Weight by Barclays
Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $33
Beam Therapeutics Analyst Ratings